Jazz Pharmaceuticals
JAZZ
295 hedge funds and large institutions have $5.68B invested in Jazz Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 93 increasing their positions, 118 reducing their positions, and 72 closing their positions.
87% more ownership
Funds ownership: 0% → 87% (+87%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
9% less funds holding
Funds holding: 325 → 295 (-30)
12% less capital invested
Capital invested by funds: $6.48B → $5.68B (-$804M)
21% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 118
35% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 72
37% less call options, than puts
Call options by funds: $41.4M | Put options by funds: $65.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
+$84.8M |
| 2 |
Renaissance Technologies
New York
|
+$71.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$52.9M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$34.1M |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$33.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$144M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$89.6M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$63.9M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$42.2M |
| 5 |
Goldman Sachs
New York
|
-$36.9M |
JAZZ Hedge Fund Activity: Q4 2016 in Review
295 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2016, worth a combined $5.68B — down 12% from $6.48B a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of JAZZ and 47 opened new positions — a net loss of 25 holders — while 118 trimmed existing stakes and 93 added.
The largest buyer was Tourbillon Capital Partners, adding an estimated $84.8M. The largest seller was Fidelity Investments, cutting an estimated $144M.
- 295 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2016, down from 325 in Q3 2016.
- Funds reported $5.68B of Jazz Pharmaceuticals stock for Q4 2016, down 12% quarter-over-quarter.
- 47 funds opened new Jazz Pharmaceuticals positions in Q4 2016 and 72 closed out, a net change of -25 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2016 was Tourbillon Capital Partners, an estimated $84.8M added.
- The largest Jazz Pharmaceuticals seller in Q4 2016 was Fidelity Investments, an estimated $144M sold.
Based on aggregated 13F filings for Q4 2016.